Christophe Morice

USPTO Granted Patents = 10 (Patent Applications = 14)

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Widensolen, FR (2010 - 2016)
Illkirch, FR (2017 - 2018)

Company Filing History:

3 out of 2,405

Merck Sharp + Dohme Corp.

Savira Pharmaceuticals Gmbh

patents

5. 1 out of 168

F. Hoffmann-la Roche Ag

patents

6. 1 out of 64

European Molecular Biology Laboratory

patents

7. 1 out of 1

Prestwick Chemical, Inc.

patent

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331022 - Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors (2025-06-17),

2. 12275732 - Cyclic compounds as receptor modulating therapeutics and methods and uses thereof (2025-04-14),

3. 12139473 - Substituted-N-heteroaryl compounds and uses thereof (2024-11-12),

4. 12090146 - Substituted-pyridinyl compounds and uses thereof (2024-09-17),

5. 9994518 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof (2018-06-12),

6. 9790173 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I (2017-10-17),

7. 9434745 - 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease (2016-09-06),

8. 8962627 - Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors (2015-02-24),

9. 8071590 - 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials (2011-12-06),

10. 7713965 - 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials (2010-05-11),

Title: Christophe Morice: Pioneering Innovation in Neurodegenerative Disease Treatment

Introduction:

Christophe Morice, a talented inventor hailing from Widensolen, France, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 6 patents to his name, Morice's work focuses on developing compounds for the treatment of neurodegenerative diseases such as Alzheimer's, schizophrenia, and Parkinson's.

Latest Patents:

Morice's latest patents revolve around Alpha-7 nicotinic acetylcholine receptor modulators and their diverse applications in the field of medicine. These compounds hold immense potential in positively modulating the alpha 7 nicotinic acetylcholine receptors, particularly in regions like the cerebral cortex and hippocampus. They offer promising avenues for treating neurodegenerative conditions and movement disorders associated with Parkinson's disease.

Career Highlights:

Throughout his career, Morice has worked with esteemed companies such as Merck Sharp & Dohme Corporation and Vetoquinol S.A. In these roles, he has demonstrated exceptional skills in research and innovation, leading to the development of groundbreaking pharmaceutical compounds.

Collaborations:

Morice's collaborative efforts have been instrumental in his success. Working alongside talented individuals like Bruno Giethlen and Andrew John Harvey, he has been able to harness a diverse range of expertise to further his research in the field of neurodegenerative disease treatment.

Conclusion:

Christophe Morice's inventive spirit and dedication to advancing medical science have paved the way for novel approaches in tackling complex diseases. His contributions to the field of pharmaceuticals underscore his commitment to improving patient outcomes and addressing unmet medical needs. With a bright future ahead, Morice continues to drive innovation and make a lasting impact in the realm of neurodegenerative disease treatment.

This text is generated by artificial intelligence and may not be accurate.